Rafaèle Elisabeth Tordjman
Fondatore presso Women Innovating Together In Healthcare
Provenienza dei contatti di primo grado di Rafaèle Elisabeth Tordjman
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Sofinnova Partners SAS
 Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.
28
| Private Company | Investment Managers | 28 |
| Public Company | Pharmaceuticals: Major | 25 | |
| Public Company | Pharmaceuticals: Major | 20 | |
19
| Public Company | Pharmaceuticals: Major | 19 |
| Subsidiary | Pharmaceuticals: Major | 17 | |
14
| Public Company | Miscellaneous Commercial Services | 14 |
Alentis Therapeutics AG
 Alentis Therapeutics AG Pharmaceuticals: MajorHealth Technology Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland.
9
| Holding Company | Pharmaceuticals: Major | 9 |
CDR-Life Inc.
 CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017.
5
| Holding Company | Biotechnology | 5 |
MedDay Pharmaceuticals SAS
 MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France.
4
| Holding Company | Biotechnology | 4 |
ENYO Pharma SA
 ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.
1
| Holding Company | Biotechnology | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Rafaèle Elisabeth Tordjman tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| GILEAD SCIENCES, INC. | Biotechnology | Chief Tech/Sci/R&D Officer General Counsel | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| INTERMUNE INC | Biotechnology | Chief Tech/Sci/R&D Officer Director/Board Member Director/Board Member | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Secretary Director of Finance/CFO Corporate Officer/Principal Corporate Officer/Principal | |
| IPSEN | Pharmaceuticals: Major | Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal | |
| VELOXIS PHARMACEUTICALS A/S | Pharmaceuticals: Major | Director of Finance/CFO Chairman Director of Finance/CFO Director of Finance/CFO | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
Calliditas Therapeutics Suisse SA
 Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Generic | Chairman Director/Board Member | |
Sofinnova Investments, Inc.
 Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Investment Managers | Private Equity Investor Private Equity Investor Corporate Officer/Principal | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| The Trustees of Columbia University in The City of New York | College/University | Graduate Degree Masters Business Admin Masters Business Admin | |
| Stanford University | College/University | Undergraduate Degree Doctorate Degree Masters Business Admin | |
| NTG NORDIC TRANSPORT GROUP A/S | Trucking | Director/Board Member Chief Executive Officer Corporate Officer/Principal | |
| ALK-ABELLÓ A/S | Biotechnology | Chief Tech/Sci/R&D Officer Director of Finance/CFO Corporate Officer/Principal | |
Varioptic SA
 Varioptic SA Electronic ComponentsElectronic Technology Varioptic SA manufactures autofocus lens for digital imaging applications. The firm offers liquid lenses for development of electrowetting technology to create variable focus lenses with no moving parts. The company was founded by Bruno Berge in 2002 and is headquartered in Lyon, France. | Electronic Components | Director/Board Member Director/Board Member | |
| Yale University | College/University | Undergraduate Degree Graduate Degree Undergraduate Degree | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
| Copenhagen Business School | College/University | Graduate Degree Graduate Degree Graduate Degree | |
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Miscellaneous Commercial Services | Founder Corporate Officer/Principal Corporate Officer/Principal | |
| University of Copenhagen | College/University | Graduate Degree Undergraduate Degree Doctorate Degree Graduate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| University of Pavia | College/University | Doctorate Degree Undergraduate Degree | |
| ESSEC Business School | College/University | Undergraduate Degree Undergraduate Degree | |
| École des Hautes Études Commerciales de Paris | College/University | Undergraduate Degree Masters Business Admin Graduate Degree | |
BPIFrance Investissement SAS
 BPIFrance Investissement SAS Investment ManagersFinance BPIFrance Investissement SAS (BPIfrance Investissement) is the private equity arm and subsidiary of State-owned Banque Publique d'Investissement in France. Formerly known as CDC Entreprises SAS, the firm was established in 1994 to carry out public-interest missions such as employment creation and momentum initiation in the private equity field. In 2013 they became BPIfrance Investissement when CDC Entreprises, FSI and FSI Régions merged. Headquartered in Paris, BPIfrance Investissement invests of behalf of the Government of France, as well as for third parties including FEI-Fonds Européen d'Investissement, BEI-Banque Européenne d'Investissement and BPCE SA. The firm invests directly or indirectly in SMEs and intermediate-sized companies at all stages of their development. | Investment Managers | Private Equity Investor General Counsel | |
Crescendo Biologics Ltd.
 Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
MISSION Therapeutics Ltd.
 MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Panmira Pharmaceuticals LLC
 Panmira Pharmaceuticals LLC Pharmaceuticals: OtherHealth Technology Panmira Pharmaceuticals LLC provides drug development programs. It develops pharmaceutical products for inflammatory diseases. The company was founded in September 2011 and is headquartered in San Diego, CA. | Pharmaceuticals: Other | Director/Board Member Chairman | |
| PIXIUM VISION | Medical Specialties | Founder Director/Board Member Director/Board Member | |
| AUDENTES THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chairman Director of Finance/CFO | |
Inotrem SA
 Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | Biotechnology | Director/Board Member Director/Board Member | |
| BOLT BIOTHERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Therachon SAS
 Therachon SAS BiotechnologyHealth Technology TherAchon SAS provides biotechnology services. It specializes in research and development for achondroplasia and its associated complications. The company was founded by Elvire Gouze in 2014 and is headquartered in Biot, France. | Biotechnology | Director/Board Member Chief Executive Officer | |
| GRITSTONE BIO, INC. | Biotechnology | Chairman Chairman | |
Brainever SAS
 Brainever SAS Pharmaceuticals: MajorHealth Technology Brainever SAS manufactures pharmaceutical products. It develops medicines for nervous system diseases. The company was founded on March 31, 2015 and is headquartered in Paris, France. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| KALVISTA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
DNA Script SAS
 DNA Script SAS Medical SpecialtiesHealth Technology DNA Script engages in the provision of research and development in biotechnology. It manufactures synthetic deoxyribonucleic acid using enzymatic technology. The company was founded by Thomas Ybert, Sylvain Gariel and Xavier Godron in 2014 and is headquartered in Paris, France. | Medical Specialties | Director/Board Member Director/Board Member | |
Pureos Partners AG
 Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member Director/Board Member Founder | |
Comet Biorefining, Inc.
 Comet Biorefining, Inc. BiotechnologyHealth Technology Comet Biorefining, Inc. operates as a holding company, which engages in the provision of cellulosic glucose technology for applications in renewable biofuels and biochemicals. It proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosic glucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. The company was founded by Andrew Richard in 2009 and is headquartered in London, Canada. | Biotechnology | Director/Board Member Director/Board Member |
Statistiche
Distribuzione geografica
| Stati Uniti | 17 |
| Francia | 13 |
| Svizzera | 9 |
| Danimarca | 7 |
| Regno Unito | 5 |
Settori
| Health Technology | 32 |
| Consumer Services | 11 |
| Commercial Services | 4 |
| Finance | 4 |
| Transportation | 2 |
Posizioni
| Director/Board Member | 800 |
| Corporate Officer/Principal | 231 |
| Independent Dir/Board Member | 196 |
| Chairman | 158 |
| Chief Executive Officer | 83 |
Contatti più connessi
| Insiders | |
|---|---|
| Peter Hutt | 69 |
| James Healy | 50 |
| Ed Mathers Mathers | 47 |
| Andrew Schwab | 45 |
| Heath Lukatch | 43 |
| Jonathan Silverstein | 42 |
| Bradley Bolzon | 41 |
| Elaine Jones | 37 |
| Bernard Gilly | 32 |
| Mette Agger | 30 |
| Albert Cha | 30 |
| Catherine Moukheibir | 29 |
| Torbjørn Bjerke | 27 |
| Chahra Khaoua Epouse Louafi | 26 |
| Graziano Seghezzi | 26 |
- Borsa valori
- Insiders
- Rafaèle Elisabeth Tordjman
- Connessioni Società
